Comparing the current results to its competitors, Igm Biosciences Inc reported Revenue increase in the 2 quarter 2025 by 11353.19 % year on year. The sales growth was above Igm Biosciences Inc 's competitors' average revenue growth of 9.57 %, achieved in the same quarter.
Igm Biosciences Inc 's Comment on Competition and Industry Peers
The company operates in the pharmaceutical and biotechnology industry, focusing on autoimmune therapies. Its competitors include multinational pharmaceutical companies, established biotechnology firms, specialty pharmaceutical companies, universities, academic institutions, government agencies, and other research organizations. Notable competitors include AbbVie, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Johnson and Johnson, Novartis, Pfizer, and Takeda. These competitors often possess greater financial resources and expertise in research and development, manufacturing, clinical trials, regulatory approvals, and marketing. Industry consolidation through mergers and acquisitions may further concentrate resources among fewer competitors. Additionally, smaller or early-stage companies can be significant competitors, particularly through collaborations with larger companies.
April 17, 2024
In a significant strategic shift, IGM Biosciences, a clinical-stage biotechnology company focused on building integrated antibody solutions, has decided to refocus its collaboration with Sanofi, the French multinational pharmaceutical company. The mutual understanding now primarily aims at advancing therapies for patients across multiple inflammatory diseases, intending to serve an ever-increasing demand for advanced and effective treatments.The collaboration is set to align with Sanofi s ongoing commitment to enriching the sector of immunology and inflammation - an area of medicine of burgeoning growth and high demand. This recalibration signifies a realignment of strategic priorities for IGM Biosciences. I...
In recent news, IGM Biosciences Inc has unveiled its strategic pipeline prioritization and extended its cash runway. The company has emphasized the clinical development of its DR5 agonist in colorectal cancer and T cell engagers in autoimmune diseases. Additionally, comparing its revenue growth to its competitors, IGM Biosciences reported a 0% increase in revenue in the third quarter of 2023, which fell below the average revenue growth of its competitors. Let s delve deeper into these developments and evaluate their impact on the company.
IGM Biosciences Inc has recently announced its strategic pipeline prioritization and cash runway extension, outlining its focus on two significant areas:...
Akari Therapeutics Plc is a biopharmaceutical company that develops and commercializes treatments for autoimmune and inflammatory diseases. Their business model revolves around conducting research, clinical trials, and obtaining regulatory approvals for their product candidates. They aim to provide innovative therapies to patients and generate revenue through the sale and licensing of their products.
Avidity Biosciences Inc's business model revolves around developing and commercializing potential therapeutics using its proprietary AOC platform, which enables the targeted delivery of drugs to specific cells in the body.
Oncolytics Biotech Inc operates as a biotechnology company engaged in the development and commercialization of oncolytic viruses as potential therapeutics for the treatment of various cancers. Its business model revolves around identifying and acquiring intellectual property rights, conducting preclinical and clinical studies, and collaborating with pharmaceutical and biotechnology companies for the development and commercialization of its products. The company aims to deliver innovative and targeted cancer therapies to improve patient outcomes globally.
Kezar Life Sciences Inc is a biotechnology company that focuses on developing novel small molecule therapeutics. Their business model revolves around the discovery and development of innovative drugs to target autoimmune and inflammatory disorders, aiming to address unmet medical needs. They primarily operate by conducting extensive research and conducting clinical trials to deliver effective treatments for patients.
Iovance Biotherapeutics Inc operates on a business model centered around developing and commercializing novel cancer immunotherapy treatments. The company focuses on utilizing its proprietary Tumor Infiltrating Lymphocyte (TIL) therapy, which involves collecting and expanding a patient's own immune cells to target and kill cancer cells. Iovance primarily seeks to advance its TIL therapy candidates through clinical trials and collaborations while aiming to provide effective and personalized treatment options for cancer patients.
Sources:
Igm Biosciences Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Igm Biosciences Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
